Therapeutic Effect of Huangqi Chifengtang on Cerebral Infarction Rat Model and Its Effect on Expression of ZO-1, Claudin-5, P-gp and MRP1 Protein in Brain Tissue
|更新时间:2022-02-15
|
Therapeutic Effect of Huangqi Chifengtang on Cerebral Infarction Rat Model and Its Effect on Expression of ZO-1, Claudin-5, P-gp and MRP1 Protein in Brain Tissue
Chinese Journal of Experimental Traditional Medical FormulaeVol. 28, Issue 6, Pages: 26-33(2022)
LIU Shu-yu,WANG Qiu-yue,LIU Shu-min.Therapeutic Effect of Huangqi Chifengtang on Cerebral Infarction Rat Model and Its Effect on Expression of ZO-1, Claudin-5, P-gp and MRP1 Protein in Brain Tissue[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(06):26-33.
LIU Shu-yu,WANG Qiu-yue,LIU Shu-min.Therapeutic Effect of Huangqi Chifengtang on Cerebral Infarction Rat Model and Its Effect on Expression of ZO-1, Claudin-5, P-gp and MRP1 Protein in Brain Tissue[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(06):26-33. DOI: 10.13422/j.cnki.syfjx.20220643.
Therapeutic Effect of Huangqi Chifengtang on Cerebral Infarction Rat Model and Its Effect on Expression of ZO-1, Claudin-5, P-gp and MRP1 Protein in Brain Tissue
To explore the therapeutic effect and mechanism of Huangqi Chifengtang on middle cerebral artery embolism(MCAO) rat model.
Method
2
The 90 SPF male rats were randomly divided into sham operation group, model group, high, medium and low dose groups of Huangqi Chifengtang (8.10,4.05,2.025 g·kg
-1
) and positive drug group (Naoxintong 0.32 g·kg
-1
). MCAO rat model was established and intervened with Huangqi Chifengtang, and the neurological scores of each group were scored. The area of cerebral infarction was calculated by 2,3,5-triphenyltetrazolium chloride (TTC) staining. Serum interleukin-6 (IL-6) and interleukin-1
β
(IL-1
β
) were detected by enzyme-linked immunosorbent assay (ELISA),The contents of matrix metalloproteinase-9(MMP-9), vascular endothelial growth factor(VEGF) and vascular endothelial growth factor receptor 2 (VEGFR2), the pathological changes of brain tissue in each group were observed by hematoxylin eosin (HE) staining. Western blot was used to detect zonule atresia protein-1(ZO-1), tight junction protein-5(Claudin-5) and P-glycoprotein (P-gp) and multidrug resistance protein 1(MRP1).
Result
2
Compared with the sham operation group, the neurological function score and cerebral infarction rate of the model group were significantly increased(
P
<
0.01), and the levels of IL-6, IL-1
β
and MMP-9 in serum were significantly increased(
P
<
0.01), the levels of ZO-1 and Claudin-5 protein expression decreased significantly(
P
<
0.01), and the levels of P-gp and MRP1 protein expression increased significantly(
P
<
0.01). Compared with the model group, the neurological function score of rats in each administration group decreased significantly at 14 days (
P
<
0.05,
P
<
0.01), the pathological changes of brain tissue effectively improved, the rate of cerebral infarction significantly reduced (
P
<
0.01), and the expression level of IL-6, IL-1
β
and MMP-9 in serum decreased significantly (
P
<
0.05,
P
<
0.01), the content of VEGFR2 increased significantly (
P
<
0.01), and the content of VEGF increased significantly in high, medium dose and positive drug groups (
P
<
0.05,
P
<
0.01). Although it decreased in low dose group, there was no significant difference. The levels of ZO-1 and Claudin-5 protein expression in brain tissue of high dose group and positive drug group increased significantly (
P
<
0.05,
P
<
0.01), the level of MRP1 and P-gp protein expression decreased significantly (
P
<
0.05).
Conclusion
2
Huangqi Chifengtang can play a therapeutic role in rats with cerebral infarction by improving the pathological changes of brain tissue, reducing inflammatory reaction, promote angiogenesis and regulating the function of blood-brain barrier(BBB).
WANG W , JIANG B , SUN H , et al . Prevalence,incidence,and mortality of stroke in China:results from a nationwide population-based survey of 480 687 adults [J]. Circulation , 2017 , 135 ( 8 ): 759 - 771 .
LEE J H , JEONG S N . A population-based study on the association between periodontal disease and major lifestyle-related comorbidities in South Korea:an elderly cohort study from 2002-2015 [J]. Medicina (Kaunas) , 2020 , 56 ( 11 ): 575 .
WANG Q Y , ZHANG N , LIU S Y , et al . Saposhnikoviae Radix enhanced the angiogenic and anti-inflammatory effects of Huangqi Chifeng Tang in a rat model of cerebral infarction [J]. Evid Based Complement Alternat Med , 2021 , 2021 : 4232708 .
SHI Y H , ZHANG X L , YING P J , et al . Neuroprotective effect of Astragaloside Ⅳ on cerebral ischemia/reperfusion injury rats through Sirt1/mapt pathway [J]. Front Pharmacol , 2021 , 12 : 639898 .
LI L , GAN H , JIN H , et al . Astragaloside Ⅳ promotes microglia/macrophages M2 polarization and enhances neurogenesis and angiogenesis through PPAR γ pathway after cerebral ischemia/reperfusion injury in rats [J]. Int Immunopharmacol , 2021 , 92 : 107335 .
LIU R , ZHENG Y , HAN T , et al . Angiogenic actions of paeoniflorin on endothelial progenitor cells and in ischemic stroke rat model [J]. Am J Chin Med , 2021 , 49 ( 4 ): 863 - 881 .
LI C , SUN T , JIANG C . Recent advances in nanomedicines for the treatment of ischemic stroke [J]. Acta Pharm Sin B , 2021 , 11 ( 7 ): 1767 - 1788 .
GUO P , JIN Z , WU H , et al . Effects of irisin on the dysfunction of blood-brain barrier in rats after focal cerebral ischemia/reperfusion [J]. Brain Behav , 2019 , 9 ( 10 ): e01425 .
ZHANG H T , ZHANG P , GAO Y , et al . Early VEGF inhibition attenuates blood-brain barrier disruption in ischemic rat brains by regulating the expression of MMPs [J]. Mol Med Rep , 2017 , 15 ( 1 ): 57 - 64 .
XU J , ZHANG P , CHEN Y , et al . Sodium tanshinone Ⅱ A sulfonate ameliorates cerebral ischemic injury through regulation of angiogenesis [J]. Exp Ther Med , 2021 , 22 ( 4 ): 1122 .
CHAN S J , ESPOSITO E , HAYAKAWA K , et al . Vascular endothelial growth factor 165-binding heparan sulfate promotes functional recovery from cerebral ischemia [J]. Stroke , 2020 , 51 ( 9 ): 2844 - 2853 .
WEN J , QIAN S , YANG Q , et al . Overexpression of Netrin-1 increases the expression of tight junction-associated proteins,Claudin-5,Occludin,and ZO-1,following traumatic brain injury in rats [J]. Exp Ther Med , 2014 , 8 ( 3 ): 881 - 886 .
ZHANG Q , TAN J , WAN L , et al . Increase in blood-brain barrier permeability is modulated by tissue kallikrein via activation of bradykinin B1 and B2 receptor-mediated signaling [J]. J Inflamm Res , 2021 , 14 : 4283 - 4297 .
XIAO H , LIU J , HE J , et al . 17 β -estradiol attenuates intracerebral hemorrhage-induced blood-brain barrier injury and oxidative stress through SRC3-mediated PI3K/Akt signaling pathway in a mouse model [J]. ASN Neuro , 2021 , 13 : 17 .
DEMARS K M , YANG C , HAWKINS K E , et al . Spatiotemporal changes in p-glycoprotein levels in brain and peripheral tissues following ischemic stroke in rats [J]. J Exp Neurosci , 2017 , 11 : 117 .
WANG F , JI S , WANG M , et al . HMGB1 promoted P-glycoprotein at the blood-brain barrier in MCAO rats via TLR4/NF- κ B signaling pathway [J]. Eur J Pharmacol , 2020 , 880 : 173189 .
VERSCHEIJDEN L , VAN HATTEM A C , PERTIJS J , et al . Developmental patterns in human blood-brain barrier and blood-cerebrospinal fluid barrier ABC drug transporter expression [J]. Histochem Cell Biol , 2020 , 154 ( 3 ): 265 - 273 .
Exploring Mechanism of Kelong Capsules in Treatment of Benign Prostatic Hyperplasia Based on Nrf2 Pathway and Macrophage Activation
Zhenzhu Tiaozhi Capsules Reduce Renal Lipid Deposition and Inflammation in Mouse Model of Diabetic Kidney Disease via SCAP-SREBP-1c/NLRP3 Signaling Pathway
Establishment and Evaluation of Mouse Model of Cerebral Infarction with Qi and Yin Deficiency Syndrome Based on Metabolomics
Inhibition of Angiogenesis by Sanguisorbae Radix and Sophorae Flos in Ulcerative Colitis Mice by Regulating PI3K/Akt Signaling Pathway
Multidimensional Analysis of Mechanisms of Nuciferine Against Cerebral Ischemia Based on Transcriptomic Data
Related Author
SONG Guanhui
FAN Danping
LI Yan
LIU Hong
PAN Jinghua
WANG Shaojun
FAN Xiang
SUN Jian
Related Institution
The First Clinical Medical College of Shaanxi University of Chinese Medicine
Experimental Research Center,China Academy of Chinese Medical Sciences
Beijing University of Chinese Medicine
Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University
Beijing Key Laboratory of Chinese Materia Pharmacology,National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases,Institute of Basic Medical Sciences, Xiyuan Hospital,China Academy of Chinese Medical Sciences